Armata Pharmaceuticals Announces Second Quarter Results and Provides General Corporate Update prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Armata Pharmaceuticals Announces First Quarter Results and Provides General Corporate Update
Company earns $750,000 milestone payment related to SWARM-P.a. Study
News provided by
Share this article
Share this article
MARINA DEL REY, Calif., May 13, 2021 /PRNewswire/ Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced results for the first quarter of 2021 and provided a corporate update.
First Quarter 2021 and Recent Highlights:
Continued to advance the single ascending dose (SAD) cohort of the SWARM-
P.a. Phase 1b/2a clinical trial evaluating AP-PA02 as a potential treatment for cystic fibrosis patients with chronic